124 related articles for article (PubMed ID: 23857800)
1. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Takahashi S; Suzuki M; Uchiyama M
Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
[TBL] [Abstract][Full Text] [Related]
2. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
4. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
5. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
6. Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED; Keating GM
CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with blonanserin for drug-induced hyperprolactinemia in chronic schizophrenia patients: a six-month follow-up of two cases.
Kito S; Hasegawa T; Nakajima T; Koga Y; Hibi S; Tobe Y; Mochida M
J Neuropsychiatry Clin Neurosci; 2013; 25(3):E29-30. PubMed ID: 24026734
[No Abstract] [Full Text] [Related]
8. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Li H; Yao C; Shi J; Yang F; Qi S; Wang L; Zhang H; Li J; Wang C; Wang C; Liu C; Li L; Wang Q; Li K; Luo X; Gu N
J Psychiatr Res; 2015 Oct; 69():102-9. PubMed ID: 26343601
[TBL] [Abstract][Full Text] [Related]
9. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
10. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Kishi T; Matsuda Y; Iwata N
PLoS One; 2014; 9(2):e88049. PubMed ID: 24505373
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
[TBL] [Abstract][Full Text] [Related]
12. Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Harvey PD; Nakamura H; Murasaki M
Neuropsychopharmacol Rep; 2019 Sep; 39(3):173-182. PubMed ID: 31041855
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1361-2. PubMed ID: 20647025
[No Abstract] [Full Text] [Related]
15. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Harvey PD; Nakamura H; Miura S
Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
[TBL] [Abstract][Full Text] [Related]
16. Blonanserin. AD 5423.
Drugs R D; 2002; 3(6):405-6. PubMed ID: 12516946
[No Abstract] [Full Text] [Related]
17. Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
Yu W; Lei L; Yu Y; Li Y; Shen Y; Li H
Hum Psychopharmacol; 2020 Jan; 35(1):e2717. PubMed ID: 31837240
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kishi T; Matsui Y; Matsuda Y; Katsuki A; Hori H; Yanagimoto H; Sanada K; Morita K; Yoshimura R; Shoji Y; Hagi K; Iwata N
Pharmacopsychiatry; 2019 Feb; 52(2):52-62. PubMed ID: 29514360
[TBL] [Abstract][Full Text] [Related]
19. One-Year Follow-Up of Serum Prolactin Level in Schizophrenia Patients Treated with Blonanserin: A Case Series.
Takahashi S; Suzuki M; Uchiyama M
Psychiatry Investig; 2015 Oct; 12(4):566-8. PubMed ID: 26508971
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
